IDEAYA Biosciences Inc. (NASDAQ: IDYA) will present complete data from its Phase 2/3 registrational trial OptimUM-02 at the 2026 American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE